NanoString Technologies Inc, Seattle, and HalioDx SAS, Marseille, France, have entered into an agreement to develop and commercialize advanced gene expression assays for assessing patient response to immunotherapies.
Under the collaboration agreement, NanoString and HalioDx will jointly develop innovative immune gene expression assays based on discoveries of Jérôme Galon, PhD, research director at the Institut National de la Santé et de la Recherche Médicale and his team at Cordeliers Research Center. The assays will be performed on the NanoString nCounter analysis system. NanoString and HalioDx will offer products and associated services to academic, pharmaceutical, and biotechnology customers worldwide.
The products and services to be developed under the collaboration will enable researchers and drug developers to use assays to assess responses to immunotherapies and select patients who are most likely to benefit from the therapies. The collaboration seeks to expand both companies’ leadership in precision immunooncology, and offers the potential for future companion diagnostic collaborations with biopharmaceutical partners.
Vincent Fert, HalioDx.
“HalioDx is very excited to jointly develop with NanoString our innovative predictive and prognostic immune gene expression signatures on the nCounter platform, one of the best multianalyte testing platforms for translating gene expression signatures to routine diagnostic use,” says Vincent Fert, cofounder and CEO of HalioDx. “At HalioDx, we want to develop diagnostic solutions that can be easily used in routine clinical practice settings and we selected the nCounter platform because of its robustness, turnaround time, and compatibility with formalin-fixed, paraffin-embedded tissue samples. Our codeveloped immune gene expression assays will complement the breakthrough Immunoscore immunohistochemistry assay, to foster the development of more precise immunotherapies.”
Brad Gray, NanoString Technologies.
“This collaboration with HalioDx adds another powerful tool to the nCounter immunooncology toolkit to support our customers’ efforts in developing clinically validated predictive biomarkers for cancer immunotherapies,” says Brad Gray, president and CEO of NanoString Technologies. “With the ability to process small tissue samples with minimal hands-on time, NanoString’s nCounter technology provides a powerful solution to researchers and drug developers who are in search of biomarkers for precision oncology, and is ideally suited to answering complex questions in translational research in the field of immunooncology.
For more information, visit NanoString or HalioDx.
